These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 1365413)

  • 1. SCH 39166, a potential antipsychotic drug, does not evoke movement disorders in cebus monkeys.
    Coffin VL; McHuch D; Chipkin RE; Barnett A
    Neurochem Int; 1992 Mar; 20 Suppl():141S-145S. PubMed ID: 1365413
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dopamine D1 (SCH 23390) and D2 (haloperidol) antagonists in drug-naive monkeys.
    Casey DE
    Psychopharmacology (Berl); 1992; 107(1):18-22. PubMed ID: 1534177
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acute extrapyramidal syndrome in Cebus monkeys: development mediated by dopamine D2 but not D1 receptors.
    Coffin VL; Latranyi MB; Chipkin RE
    J Pharmacol Exp Ther; 1989 Jun; 249(3):769-74. PubMed ID: 2567351
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chronic treatment with the D1 receptor antagonist, SCH 23390, and the D2 receptor antagonist, raclopride, in cebus monkeys withdrawn from previous haloperidol treatment. Extrapyramidal syndromes and dopaminergic supersensitivity.
    Lublin H; Gerlach J; Peacock L
    Psychopharmacology (Berl); 1993; 112(2-3):389-97. PubMed ID: 7871047
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chronic dopamine D1, dopamine D2 and combined dopamine D1 and D2 antagonist treatment in Cebus apella monkeys: antiamphetamine effects and extrapyramidal side effects.
    Peacock L; Hansen L; Mørkeberg F; Gerlach J
    Neuropsychopharmacology; 1999 Jan; 20(1):35-43. PubMed ID: 9885783
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term treatment with low doses of the D1 antagonist NNC 756 and the D2 antagonist raclopride in monkeys previously exposed to dopamine antagonists.
    Lublin H; Gerlach J; Mørkeberg F
    Psychopharmacology (Berl); 1994 Apr; 114(3):495-504. PubMed ID: 7855208
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effects of dopamine D1 and D2 receptor agonists and antagonists in monkeys withdrawn from long-term neuroleptic treatment.
    Peacock L; Lublin H; Gerlach J
    Eur J Pharmacol; 1990 Sep; 186(1):49-59. PubMed ID: 1980891
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Extrapyramidal side effects during chronic combined dopamine D1 and D2 antagonist treatment in Cebus apella monkeys.
    Peacock L; Jensen G; Nicholson K; Gerlach J
    Eur Arch Psychiatry Clin Neurosci; 1999; 249(5):221-6. PubMed ID: 10591986
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effects of haloperidol and raclopride in the paw test are influenced similarly by SCH 39166.
    Prinssen EP; Ellenbroek BA; Stamatovic B; Cools AR
    Eur J Pharmacol; 1993 Feb; 231(2):275-80. PubMed ID: 8095900
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Haloperidol-induced catalepsy is absent in dopamine D(2), but maintained in dopamine D(3) receptor knock-out mice.
    Boulay D; Depoortere R; Oblin A; Sanger DJ; Schoemaker H; Perrault G
    Eur J Pharmacol; 2000 Mar; 391(1-2):63-73. PubMed ID: 10720636
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effects of D1 (NNC 22-0215) and D2 (haloperidol) antagonists in a chronic double-blind placebo controlled trial in cebus monkeys.
    Casey DE
    Psychopharmacology (Berl); 1995 Oct; 121(3):289-93. PubMed ID: 8584608
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Behavioural effects of dopamine D-1 and D-2 receptor agonists in monkeys previously treated with haloperidol.
    Lublin H; Gerlach J
    Eur J Pharmacol; 1988 Aug; 153(2-3):239-45. PubMed ID: 3263277
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of several partial dopamine D2 receptor agonists in Cebus apella monkeys previously treated with haloperidol.
    Peacock L; Gerlach J
    Eur J Pharmacol; 1993 Jun; 237(2-3):329-40. PubMed ID: 8103465
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of a dopamine D1/5 receptor antagonist on haloperidol-induced inhibition of the acquisition of conditioned fear.
    Inoue T; Izumi T; Li XB; Kitaichi Y; Nakagawa S; Koyama T
    Eur J Pharmacol; 2005 Sep; 519(3):253-8. PubMed ID: 16135362
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Conditioning to injection procedures and repeated testing increase SCH 23390-induced catalepsy in mice.
    Chinen CC; Frussa-Filho R
    Neuropsychopharmacology; 1999 Nov; 21(5):670-8. PubMed ID: 10516963
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dopaminergic basis for the facilitation of brain stimulation reward by the NMDA receptor antagonist, MK-801.
    Olds ME
    Eur J Pharmacol; 1996 Jun; 306(1-3):23-32. PubMed ID: 8813611
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interaction of haloperidol and SCH 23390 with cocaine and dopamine receptor subtype-selective agonists on schedule-controlled behavior of squirrel monkeys.
    Witkin JM; Schindler CW; Tella SR; Goldberg SR
    Psychopharmacology (Berl); 1991; 104(4):425-31. PubMed ID: 1838199
    [TBL] [Abstract][Full Text] [Related]  

  • 18. No change in dopamine D1 receptor in vivo binding in rats after sub-chronic haloperidol treatment.
    Sanci V; Houle S; DaSilva JN
    Can J Physiol Pharmacol; 2002 Jan; 80(1):36-41. PubMed ID: 11911224
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Catalepsy-associated behavior induced by dopamine D1 receptor antagonists and partial dopamine D1 receptor agonists in squirrel monkeys.
    Rosenzweig-Lipson S; Bergman J
    Eur J Pharmacol; 1994 Aug; 260(2-3):237-41. PubMed ID: 7988649
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aberrant behavioral effects of a dopamine D1 receptor antagonist and agonist in monkeys: evidence of uncharted dopamine D1 receptor actions.
    Peacock L; Gerlach J
    Biol Psychiatry; 2001 Oct; 50(7):501-9. PubMed ID: 11600103
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.